ipsc-deriv nk cell time nigh
pois provid platform valid initi buy
forma cash includ up-front payment
janssen april addit end cash
ipsc-deriv nk cell threshold clinic valid
semin observ lead gener induc
pluripot stem cell ipsc adult fibroblast somat
cell retrovir transduct hand morph
multipl clinic program leverag compani clonal
master ipsc line engin program multipl
applic abil incorpor multipl function
allogen ipsc-deriv off-the-shelf nk cell iter
deliber aptli demonstr evolut
gen-on program minim edit endow four
function near ind submiss next month
anticip signific clinic news flow plu ld-
expans cohort nsclc dose escal aml
combin rituximab nhl combin
avelumab r/r solid tumor preliminari activ
safeti data nhl clinic updat augment
ind submiss complet anticip
prior promis continu news flow
forese futur join enthusiasm ipsc-deriv
nk cell janssen given april world-wide collabor
span four new taa hematolog malign solid tumor
furthermor april invest gilead
rate onko-inn privat advanc nk cell-bas cancer
immunotherapi view anoth potenti come age
moment nk cell innat abil kill malign cell without
prior sensit fate stock handili outperform
group vs gain xbi given surg
interest space plethora aforement clinic
mileston believ headroom stock initi
buy target
pois build upon earli promis experi
cord blood nk improv cb-nk
includ membran express agonist form creat
fusion complex domain function
nk cell biolog contain transmembran domain
could improv outcom compar construct deriv
cell high-affin non-cleav fc receptor
modifi augment adcc enabl target
mab-induc adcc like improv upon
recent clinic experi cord blood-deriv nk latter
detect month post infus suggest
incorpor could abrog depend extern
cytokin support expans durabl rate
limit step nk cell therapi importantli clinic evid
autolog set seem confirm rapid expans
persist month along high-qual less differenti
cell primari driver robust durabl remiss henc
edit incorpor could provid clinic meaning
outcom updat expect hover around
month one orr view
definit distribut analyst rate analyst certif disclosur pleas refer page report
allogen nk cell modifi amelior cleavag circumv
challeng relat bespok natur cord blood haploident nk cell curb widespread clinic
explor especi aml latter compel increment data elabor upon subsequ furthermor
incorpor fc receptor two uniqu featur design augment anti-tumor activ high-
affin homozyg variant promot high bind affin modif block cleavag down-
regul upon nk cell activ note allel bind higher affin fc region engend greater nk-
cell activ associ improv outcom born clinic across multipl indic
current dose escal program across solid tumor combin avelumab rate
well hematolog malign singl agent limit supplement combin rituximab
roch rhhbi rate nhl fate decemb updat indic first aml patient treat
exhibit evid product chimer bone marrow morpholog detect leukemia updat aml
nhl expect estim r/r aml dor beyond three month cr rate
would compel outcom view
design synerg nk cell activ mm anti-bcma world incorpor
three edit includ address inher limit nk cell fratricid mab
potent cytokin complex could promot surviv persist elimin depend exogen cytokin
support high affin non-cleav fc receptor modifi augment adcc taken togeth
ipsc-deriv nk cell could posit ideal partner mab address sever limit
contribut develop resist includ reduct adcc adcp cdc immune-medi
process view add second taa function form bcma backbon allow
signific flexibl posit investig asset mm treatment algorithm bcma compon
optim nk cell biolog contain transmembran domain co-stim signal domain
data like estim
posit compel allogen cell program build upon two evolv premis
cell therapi first involv select target t-cell receptor constant trac
result construct uniform express oppos random integr mediat retrovir vector-bas
insert techniqu note select insert trac locu pristin adopt two
cover compani precis bioscienc buy allogen buy select target design
reduc tonic signal avert acceler t-cell differenti exhaust increas therapeut
potenc engin cell anim model demonstr tight transcript regul express
critic effect tumor erad second alter uniqu address potenti redund tradit
gener cell incorpor three immunoreceptor tyrosine-bas activ motif itam
introduc select calibr itam activ mutat second third second third itam
gener singl itam-contain mutant term drop trac locu form basi
demonstr superior vivo perform compar tradit gener
trace back uniqu cell phenotyp combin introduc gener off-the-
shelf ipsc cell line preliminari data could becom avail estim
first-gen ipsc pave way follow-on program base clean safeti profil univers
off-the-shelf ipsc-deriv nk cell product current evalu clinic specif nsclc
patient supplement monotherapi advanc solid tumor treat six infus identifi
safeti immunogen issu clinic rational stem observ primarili melanoma patient loss
heterozygos loh implic potenti resist mechan checkpoint inhibitor
monotherapi arm enrol patient across spectrum indic includ colon nsclc etc may
inher suscept icb henc sd best respons entir surpris furthermor patient
prospect select base loh cytokin supplement without expans prolifer
nk cell limit expans arm would administ cell per dose combin
ici therapi supplement expect primarili focu nsclc patient base nk cell preferenti
traffick lung howev basic establish safeti profil ipsc nk cell replac
second-gener program like includ multipl edit line program updat
anticip
valuat risk price target deriv risk-adjust sum-of-the-part analysi drive dcf
model dcf util beta termin growth rate risk premium calcul wacc
tax rate begin fy price target leverag outcom
assign rang po respect given clinic phase statu
four asset repres approxim rnpv per share respect use
fulli dilut os estim note model current valu could becom
meaning contributor given differenti profil collabor janssen
fulli consumm could gross excess exclud royalti risk factor could materi impair
thesi includ unknown durabl unanticip safeti immunogen concern clinic trial
delay emerg idiosyncrat side effect
tabl content
compani overview drug pipelin
ii catalyst calendar program overview
iv valuat analysi financi outlook
assign po rnpv weight contribut
dcf encompass asset valu
 induc pluripot stem cell foundat
vii off-the-shelf adopt nk cell immunotherapi target disrupt prevent fratricid
ix off-the-shelf nk cell deriv clonal engin master ipsc line express fc receptor
xii near-to-intermedi term financi outlook patient model
xiii commerci financi model
compani overview pioneer new class therapeut
pioneer clinic investig ipsc-deriv cell therapi cancer immunotherapi novemb
public illustr induct pluripot stem cell adult human fibroblast refer page form basi
nobel prize physiolog medicin jointli share sir john gurdon shinya yamanaka discoveri matur
cell reprogram becom pluripot thirteen year sinc semin observ therapi use master engin ipsc
line renew sourc manufactur cell therapi product enter clinic gener first-in-human safeti data cell
therapi advanc engend well-defin uniform composit mass produc scale
cost-effect manner deliv off-the-shelf broad patient access current capac individu treatment
produc per patient markedli cheaper high five figur low six figur price tag cell
preliminari data compani first-in-human off-the-shelf ips-deriv nk cell product candid unveil decemb
combin outpati lymphodeplet follow three once-weekli dose two treatment cycl
identifi safeti issu studi expand includ low dose would primarili focu nsclc patient
experienc diseas progress prior checkpoint inhibit therapi mechanist rational traffick nk cell
lung would evinc anti-tumor activ especi tumor cell loss mhc class hetergyzos latter implic one
primari resist mechan therapi note best knowledg like replac second
gener investig program multipl gene edit would render exogen cytokin support redund akin note
off-the-shelf multi-antigen target nk cell product candid deriv clonal master engin ipsc line
engin three activ anti-tumor compon
beyond decemb report outcom first patient treat open label multi-dos phase program
off-the-shelf nk cell cancer immunotherapi deriv clonal master ipsc line engin express novel high
affin non-cleav fc receptor modifi augment antibodi depend cellular cytotox relapsed/refractori
aml patient treat demonstr chimer bone marrow day show morpholog evid leukemia
evid hematopoiet recoveri provid first clinic evid anti-tumor activ
addit data expect corpor updat disclos ind
submiss complet ind expect follow thereaft
dramat expand clinic pipelin exit initi provid deeper dive overview
upcom ind
disclosur along janssen collabor
secur right bcma-car use ipsc
ind clear
sae first patient dose
clinic result sae sd first
aml patient treat morpholog leukemia
ind clear expans solid tumor
janssen rate up-front cash
equiti first patient treat
on-going clinic program potenti ind
phase protocol advanc solid tumor modifi includ support dose expans
on-going million cell per dose nsclc patient refractori relaps follow
checkpoint inhibitor therapi studi current enrol patient three site potenti data
enrol on-going dose escal segment monotherapi treatment aml
combin rituximab treatment b-cell malign studi current enrol patient three
site potenti data addit priorit develop combin
target mab avelumab patient advanc solid tumor refractori
relaps follow least one line therapi
dose escal studi open enrol march monotherapi
combin rituximab obinutuzumab subject r/r b-cell lymphoma chronic lymphocyt leukemia
preliminari data anticip
submit ind off-the-shelf crispr-edit ipsc-deriv nk cell product
candid engin three function element includ novel high affin non-cleav
fc receptor receptor fusion carri complet
knockout goal evalu construct multipl myeloma conjunct
mab program could applic tumor
expect submit ind program built backbon
dual taa-target bcma target function
expect submit ind off-the-shelf ipsc-deriv car-t cell therapi
deriv clonal master engin ipsc line engin novel target insert
t-cell receptor alpha constant locu edit complet elimin t-cell receptor express mitig
risk gvhd
ii catalyst calendar plethora clinic readout
preliminari safeti activ r/r nhl
preliminari safeti activ r/r aml
differenti neurotox profil vs auto allo
cell dose-depend increas orr
current benchmark orr cb nk
gvhd evid earli durabl dose
depend activ cr
durabl respons well receiv
safeti activ combin avelumab
patient diseas progress prior
safeti activ combin
supplement nsclc patient diseas
progress prior therapi
gvhd orr mid teen rang like
well receiv especi respons durabl
orr rang like well
especi respons durabl
nk cell use myeloma
adopt nk cell-bas immunotherapi area activ clinic investig past decad
howev clinic outcom solid tumor limit due poor persist limit expans nk cell
respons limit stabl diseas best outcom independ sourc nk cell gvhd
dose limit
furthermor requir cytokin primarili drive stimul nk cell post therapi self limit
primarili due treg
recent clinic experi cord blood- cb -deriv nk incorpor ecotop
express suggest durabl might rate limit nhl exampl nk cell detect blood
one mark improv haplo-nk cell solid tumor multipl myeloma
furthermor much like autolog cell cb-nk expans evid earli three day
infus cell persist least month respons therapi associ significantli higher earli
expans car-nk
incorpor addit advanc cb-nk could translat clinic meaning result
improv cb-nk program includ
super agonist form creat fusion complex domain mimic bio-
activ endogen trans-pres format could overcom tgf-mediat inhibit nk deriv ipsc
optim nk cell biolog contain transmembran domain could improv outcom
compar construct carri scfv cell
high-affin non-cleav fc receptor modifi augment adcc enabl target
could augment establish activ mab
deep dive refer page
high point
incorpor three edit includ address inher limit nk cell
fratricid mediat mab potent cytokin complex could promot
surviv persist elimin depend exogen cytokin support high
affin non-cleav fc receptor modifi augment adcc
taken togeth ipsc-deriv nk cell posit ideal partner mab
address sever limit contribut develop resist includ reduct
adcc adcp cdc immune-medi process view
add second taa function form bcma backbon allow
signific flexibl posit investig asset mm treatment algorithm bcma
compon optim nk cell biolog contain transmembran domain co-stim
signal domain
ind anticip respect
deep dive refer page
instead random insert via retrovir lentivir vector tumor target domain specif insert
trac locu place target control endogen regulatori element reduc
tonic signal avert acceler t-cell differenti exhaust increas therapeut
potenc engin cell anim model
singl step delet insert entir novel implement precis bioscienc
buy allogen buy albeit via distinct edit methodolog
given tradit gener cell incorpor three immunoreceptor tyrosine-bas
activ motif itam construct util novel configur itam
pursu compet platform
oth specif mutat domain imped phosphoryl second third itam
domain gener singl function itam term
drop trac locu form basi demonstr superior
vivo perform compar tradit gener account superior cell phenotyp
bottom line enhanc cell differenti acquisit effector function essenti
optim
therapeut potenc cell base comparison differ signal motif express
modifi itam configur favor persist highli function balanc replic capac
long-liv memori cell acquisit effect antitumor function
deeper dive refer page
assign probabl success po rnpv market size risk adjust npv weight contribut
dcf encompass asset valu
togeth repres rnpv
assign po rnpv
probabl
elabor upon subsequ multipl design superior
avail data cb-deriv nk demonstr orr
cb-nk-car could translat superior clinic outcom
histor data cb-nk cell haploident transplant etc point viabl
activ nk cell aml patient preliminari monotherapi data
point continu prior trend
build loh hypothesi combin fc-modifi anti-
specif exploit potenti synergi uc merkel cell
least mm patient respond monotherapi
incorpor abil specif target immune-unprivileg
patient high affin allel situ stimul abil
prevent mediat nk cell fratricid
incorpor advantag ad abil engag
target bcma alreadi valid target mm
first gener program valid safeti profil ipsc nk cell
use combin supplement soon
replac clinic next-gen program leverag situ cytokin
support along construct modif
po reflect development regulatori mileston
includ futur commerci mileston overal repres
rnpv recal fulli consumm partnership could net excess
sharehold
hcw estim launch market penetr
market size sale estim
price us
us
sale mm
risk-adjust npv captur
weight contribut asset across geographi
valu
discount beta rate yr premium equiti debt growth valu total non-cash work cash flow valu cash per inc
 induc pluripot stem cell foundat
mice men nobel prize fate ipscsth high point
first proof dedifferenti possibl transcript factor express
pluripot ipsc demonstr reproduct
nobel prize gener human ipsc somat cell
fate novel medium maintain high ipsc cultur
mice men nobel prize fate ipscsth high point
over-express c-myc transform murin fibroblast pluripot stem
murin ipsc differenti tissu bodi
over-express c-myc transform human dermal fibroblast ipsc
develop pharmacology-bas cultur medium enhanc ipsc abund
media allow episom reprogram avoid potenti oncogen transform inher
retrovir reprogram
find episom reprogram possibl use caus copy-
number variat chromosom rearrang
first proof dedifferenti possibl transcript factor express
twenty-four candid transform gene select
retrovirally-transduc mous embryon
fibroblast determin combin gene could induc
revers pluripot state found four clone
embryon stem es cell-lik morpholog prolifer rate
three round remov individu gene identifi
essenti gene necessari transform four gene c-myc
identifi necessari see
addit factor induc pluripot stem cell ipsc
coloni wherea remov individu gene result
dramat decreas effici
express profil measur rt-pcr
transduc candid gene
examin cell found
similar express level compar es cell sever es
gene exactli equival see
inject nude mice teratoma form
differenti
muscl adipos epithelium see
pluripot ipsc demonstr reproduct
tail-tip fibroblast cell seven week-old mice
transform c-myc found
exhibit morpholog characterist es cell similar gene
profil could produc teratoma three germ layer
ips-ttf clone inject mous blastocyst
allow develop embryo contribut ips-ttf
clone trace gfp express appear
contribut tissu one embryo see gfp posit cell
observ gonad clear
germlin somat cell
nobel prize gener human ipsc somat cell
induc pluripot stem cell creat somat cell
transfect four transcript factor c-myc
transfect human dermal fibroblast hdf four
transcript factor morpholog select human ipsc
isol exhibit diverg
rel parent hdf cell line see graph left
much similar embryon stem cell es see graph
right red line delin differ gene express
human ipsc depend continu express
transcript factor maintain pluripot
depend feeder cell potenti bottleneck
also express telomeras prolifer rate equival
grown suspend cultur
bodi three differenti layer ectoderm mesoderm
importantli ipsc could induc differenti neuron
cardiomyocyt see bottom phase-contrast imag
howev directli inject mice ipsc form teratoma
differenti variou cell type addit ipsc
clone found retrovir integr
fate novel medium maintain high ipsc cultur
one bottleneck cultur ipsc initi
convers somat cell ipsc subsequ
enrich mainten ipsc
use convent cultur medium cell
day appear posit
indic ipsc see
marker es cell
previous develop cocktail four inhibitor
compris mek tgf- pathway
term allow feeder-fre passag
singl cell isol result ipsc see
howev tgf- inhibit use
reprogram help mainten
dedifferenti state see tgf- inhibitor
remov formul approxim
cell maintain posit
bolster addit bfgf lif henc
deploy subsequ gener ipsc
somat cell re-porgram with
maintain fmm result cell
maintain posit day see
approxim day see
attempt use non-integr strategi deriv ipsc
labori ineffici would like safer given lower potenti
express oncogen etc
use episom
reprogram system express seven differ gene osnklmt
gener posit cell day
studi describ attempt
attempt
improv upon transfect effici previous
obtain use episom reprogram multistag reprogram
mainten regiment describ previous outlin upper
panel util conjunct seven gene episom
episom transfect four differ fibroblast line expand
pbmc abl induc
reprogram human ipsc measur
express function cultur period see panel
fmm passag
clone cultur feeder-
respect
evalu cytogenet flow-cytometri case vast
major cell maintain undifferenti posit
state respect appear
gross-chromosom rearrang base cytolog see panel
human ipsc clone induc differenti form
embryoid bodi embryoid bodi compos
development layer ectoderm mesoderm sma endoderm
attempt streamlin gene requir reprogram variou combin episom cassett
express nanong employ gener ipsc subsequ
simplest combin contain express cassett express result
induct effici around compar episom reprogram use seven gene
passag clone isol lost episom express detect
pcr assay loss plasmid-conf drug resist posit outcom limit possibl
later oncogen transform
human ipsc cell line deriv minim episom express exhibit karyotyp minim
chang copy-numb variat indic gross-chromosom rearrang duplication/delet event
occur reprogram see panel
os
vi off-the-shelf nk cell deriv clonal
nk cell-specif cell prelud
make superior activ compar tradit
first-in-human cord blood deriv nk-car activ
earli expans nk associ respons
comparison vs cb-nk focu
nk cell diseas progress wait autolog product
advantag allogen cell therapi autolog
adopt nk cell-bas immunotherapi
area activ clinic investig past decad
trial use nk cell isol peripher
blood umbil cord blood nk cell line
trial use adopt transfer allogen nk cell
demonstr safeti gvhd neurotox
typic clinic studi use combin lympho-deplet
chemotherapi cytokin treatment enabl vivo surviv
expans allogen nk cell three week
treatment
cell aneuploid must irradi
administ patient limit
surviv
prolifer nk cellstwo key criteria associ
although nk cell isol peripher blood pb-nk
cell umbil cord blood ucb-nk cell
efficaci aml success solid tumor
produc standard cell popul
provid homogen nk cell popul grown
clinic scale
engin nk cell improv kill
solid tumor evalu clinic
treatment hematolog malign
howev trial util either pb-nk cell cell
well design cell optim nk
principl
optim nk-car form basi off-
oengin nk cell activ domain improv
anti-tumor efficaci nk cell especi solid
tumor resist nk cell-medi kill
sinc primari nk cell difficult genet modifi
compar cell cell sourc switch ipsc
ipsc effici produc nk cell
genet modifi use viral non-vir method
nk cell-specif cell prelud
evalu activ cell vivo kaufman group ucsd evalu kill ovarian
cancer cell mous xenograft model model compar pb-nk cell ipsc-nk cell cell
t-car meso -ipsc-nk cell mice inocul intraperiton luciferase-express cell four day later
receiv singl inject nk cell
administr day promot vivo nk surviv expans
compar untreat tumor-bear mice treatment nk cell produc signific reduct tumor burden
day maxim anti-tumor activ seen cell day compar ipsc-
improv anti-tumor activ cell led markedli improv surviv compar ipsc-nk cell
t-car-ipsc-nk cell hr well compar pb-nk cell
vivo persist nk cell evalu separ group tumor-bear mice post-inject examin
blood spleen periton fluid presenc day cell significantli increas
circul spleen periton fluid compar pb-nk cell ipsc-nk cell day exogen cytokin
administr end cell level return level pb-nk cell ipsc-nk cell day
nk cell seen tissu demonstr previous
togeth studi demonstr nk-car-express ipsc-deriv nk cell mediat improv anti-tumor activ
compar non-car-express pb-nk cell ipsc-nk cell well improv activ compar t-car-
next page repres imag
nk cell-specif cell prelud
schemat vivo studi use luciferas luc -express
meso high cell mous xenograft model treat
pb-nk cell ipsc-nk popul cytokin
tumor burden determin weekli bioluminesc
imag superior outcom cell
efficaci bottom panel
cytometr quantif
cell popul peripher blood
periton fluid outperform
nk
spleen
kaplan-mei curv repres percent surviv
experiment group mice treat
cell best outcom
adapt cell stem cell august wainwright co
ipsc-deriv effector cell offer advantag immun therapi patient- donor-deriv platform includ scalabl
manufactur renew start cellular materi precis genet engin perform single-cel
ipsc deriv natur killer ink cell offer advantag innat reactiv stress ligand mhc downregul
potenti recruit downstream adapt respons
combin confer potent upregul phosphoryl activ plc- syk-
erk pathway nf-kb pathway
togeth suffici promot improv nk cell-medi granul cytokin product cytotox antigen-
activ also lead increas expans surviv nk-car-ipsc-nk cell enabl improv anti-tumor activ
ipsc-deriv nk cell normal karyotyp preclin vivo studi demonstr evid malign nk cell
transform hesc- ipsc-deriv nk cell inject immunodefici mice
use ipsc hesc nk cell product provid effici mean gene modif compar primari
nk cell isol peripher blood
addit express delet inhibitori receptor express cytokin potenti engin
cell enhanc anti-tumor activ reflect construct incorpor
fc receptor well receptor fusion protein
make superior activ compar tradit
transmembran region activ receptor combin
intracellular signal domain co-receptor
preclin data suggest effect configur trigger
antigen specif function respons nk cell
chimer scfv onto signal
platform produc specif vitro recognit cell lymphoma cell
short-term long-term nk cytotox assay clearanc
tumor cell respect
function
enhanc combin
autonom signal via potenti expans ink cell
without addit solubl cytokin greatli improv longev function
persist ink cell vitro anim model
ink cell modifi show enhanc function
matur includ upregul express effector molecul
ink cell result enhanc
function vitro mous model cell malign demonstr
treatment ink cell engin
cur cell
lymphoma compar ink cell
alon ink cell modifi alon
combin co-express
culmin ink cell capabl dual-specif combinatori use
mab tackl antigen escap
deeper respons compar
primari combin
rituximab raji parent
vivo show equival level tumor cell clearanc primari
cell cell line burkitt
tumor cell
combin rituximab
line raji enhanc clearanc raji
prevent antigen escap
combin rituximab
furthermor util allogen human engraft nsg mous model
demonstr improv surviv safeti primari cell
either monotherapi combin therapi rituximab versu raji
adapt wainwright co
enter multi-year research collabor dr kaufman univers
california san diego develop off-the-shelf ipsc-deriv nk cell cancer immunotherapi stem
aforement collabor
proprietari optim nk cell biolog contain transmembran domain
co-stimulatori domain signal domain
high-affin non-cleav fc receptor modifi augment adcc enabl target
receptor fusion enhanc surviv prolifer trans-activ nk cell
cell without need system cytokin support
adapt present wainwright co
phase on-going monotherapi rituximab combin
enabl dual target
dose first patient phase studi
disclos april
phase program design open-
monotherapi patient
combin rituximab
patient advanc b-cell
lymphoma
previous fail progress
rituximab regimen
combin obinutuzumab
patient chronic lymphocyt leukemia
previous fail progress
phase program evalu
dose escal regimen would
million million million million
treatment regimen regimen
maximum toler dose
determin regimen dose escal
first-in-human cord blood deriv nk-car activ
construct includ scfv signal
endodomain along induc caspas built
construct earli sign activ evid patient
experienc cr respons rapid seen dose level
respons durat assess administr
therapi
patient dlbcl cll fl
median age year
median four prior line therapi
receiv cord blood deriv nk
chemotherapi flu mg
cy daili consecut
day car-nk cell administ
escal dose cell cell
cells/kg bodi weight
patient respons treatment
occur first month
patient
mismatch product possibl
assess effect kir ligand mismatch
outcom small seri
earli expans nk associ respons
patient respons car-nk therapi
underw postremiss therapi patient underli cll
subsequ mrd month nk receiv
rituximab patient also cll cr persist
mrd receiv lenalidomid begin week
nk infus patient subject transform fl patient
fl underw hsct car-nk cr without
evid mrd patient cll richter
transform remiss high-grad lymphoma
persist cll receiv venetoclax patient
aliv cr date
last assess
although patient continu mrd posit
disappear week infus properti limit
clinic util howev nk activ evid low
level
least month despit substanti hla
mismatch infus nk cell recipi
inclus construct may play import
role persist antitumor activ car-nk
cell bode well
nk expans seen earli day infus
cell persist least month peak car-nk
copi number measur day infus
dose-depend day report
patient treat car-t cell respons therapi
associ significantli higher earli expans car-nk
comparison vs cb-nk focu
nk cell unabl surviv extend period time
without signal promot sustain express
known essenti nk cell function bind
heterodim surfac nk cell induc activ
-associ tyrosin kinas
n/a like episom
optim nk cell biolog
fc receptor augment adcc
preclin data identifi
turn
lead recruit activ
culmin transcript gene requir
surviv cytotox gzmb
demonstr murin nk cell
treatment would promot expans lymphocyt express
invari cell nk cell
cell
signal pathway
furthermor super agonist
form creat fusion
complex domain mimic bio-
format overcom tgf -- mediat
inhibit nk
notabl cb-nk cell control tumor expans
prolong surviv better
cb-nk cell transduc
without underscor vital contribut
intraperiton administr
human associ signific toxic earli mortal
treatment-rel mortal defin death day
compar nk cell
low dose
similar vein administr high dose
cb-nk activ nk cell transduc may
also caus similar t-cell potenti
caus toxic human suggest finit dose window
monotherapi combin clinic program schema
first patient dose april
off-the-shelf nk cell
diseas progress wait autolog product
note public compani mention includ kite subsidiari gilead rate novarti nv rate juno subsidiari bristol-my
squibb rate
sattva neelapu present
shown number patient treat
percent total patient enrol three pivot studi r/r nhl
approxim patient infus due
diseas progress manufactur period
mani patient third line set progress quickli
week vein-to-vein time rate limit
slow commerci uptak auto-car ts due facil requir
annual us
number
number
number cell
number patient treat show much slower growth column
reflect stall sale yescarta top right slow increas
kymriah partial driven later approv eu japan
slow uptak driven approv center us
requir train staff deal inabl patient travel
center low commun oncologist awar reimburs
issu due high cost product high cost support
care follow treatment hospit make loss overal
cost care despit reimburs primari product
allogen ts like substanti cheaper could also
use bridg therapi
 wainwright co adapt cibmtr annual report februari
nhl short window opportun may need
r-chop cure dlbcl patient persist
long term suggest
cancer cell elimin
within first month
long-term persist
previou studi indic persist ts
period long year associ sustain cr
loss ts associ relaps
abstract report mrd statu day r/r
dlbcl patient treat yescarta significantli
correl os
day patient mrd- went maintain
cr patient mrd progress
furthermor signific differ os stratifi
mrd statu day observ
data suggest activ may necessari
first day treatment
thu believ persist day
assum robust expans around day suffic
importantli respons mrd neg day
like sustain
poster present clin oncol suppl abstr
kymriah data sourc clinic cancer research
corrobor cb-nk experi
twenti patient either cll dlbcl mcl median four prior hsct
treat allogen cell deriv sibl hla-match donor
overal orr four six patient
new-onset gvhd develop patient like cell
deriv sibl hla-match donor
expans high ratio associ respons
owe compar statist mean across sever hematolog paramet orr
individu indic found best correl percent infus cell
ratio infus car-posit cell
 wainwright co analysi clinic oncolog april
auto competit profil
domain deriv
compar
high due use
high consist due integr
variabl due lentivir mediat
variabl due lentivir mediat
trac locu
singl non-cod site
week patient wait
cell make unlik
kymriah juliet studi convers total cell assum kg patient public compani mention includ allogen buy
precis bioscienc file precis bioscienc jp morgan rate present molecular therapi volum issu april page
scienc translat medicin allogen present
vii off-the-shelf adopt nk cell immunotherapi target
disrupt prevent antibody-medi fratricid
resist observ mm patient
introduc design overcom endogen nk cell defici optim
adopt nk cell therapi four function
lesson bcma-target cell
nk cell express high level
induct
fratricid upon treatment mab
standard care mm patient diseas progress
one prior line therapi might limit clinic impact
ex vivo data highlight chang nk cell lymphocyt
popul pbmc healthi donor treat
differ shown top pane data indic anti-
mab-medi nk-cell reduct specif
immun cell type cell cell unaffect
retrospect analysi part
siriu studi indic nk cell
peripher blood well marrow compart exhibit dose
lysi mm patient treat mab
oimportantli nk cell recov cessat treatment
predict recoveri rate approxim
per week mg/kg dose respect post
nk cell fratricid seem impact orr
orr patient divid quartil base top baselin nk-
cell count middl maximum nk-cell reduct bottom nk-cell
recoveri rate number right show mean
confid interv orr quartil number
patient respond group quartil
patient receiv mg/kg differ
orr stratifi quartil basi baselin nk-cell
count maximum nk-cell reduct recoveri rate nk cell
furthermor logist regress analys confirm lack
statist signific relationship orr baselin nk-
cell count maximum reduct nk cell
recoveri rate nk cell
impact
hr accord patient divid quartil base
bottom nk-cell recoveri rate
median patient baselin nk-
cell count month respect median
durat maximum nk-cell reduct
month respect nk recoveri rate
month respect cox proport hazard model
show hr consist across differ quartil
baselin nk-cell count maximum nk-cell reduct recoveri
rate nk cell hr close one
although nk cell greatli reduc mab
treatment cell complet deplet thu may still
enabl adcc contribut clinic efficaci effector cell
granulocyt deplet also
capabl mediat adcc may contribut efficaci
monotherapi respons darzalex sub thought
sever mechan contribut develop
resist includ reduct adcc adcp cdc
resist trace clonal select mm
cell reduct via endocytosi trogocytosi
granulocyt monocyt via releas
downregul intracellular pathway bmsc decreas
effector memori cell macrophag
co-
stimulatori express cell
overexpress
membrane-associ
complement-inhibitori protein prevent
cdc mm cell overexpress recogn
sirp tam inhibit adcp deplet nk
activ adcc requir engag fcr express
effector cell differ variant fcr relat
respons
associ higher affin fc fragment mab
higher adcc activ contrast fcriib
fcr
variant express nk cell may modul
introduc design overcom endogen nk cell defici
optim activ
modifi
delet
potent cytokin complex could
promot surviv persist reduc
depend exogen cytokin support
adopt corpor present wainwright co
optim vitro activ
posit overcom endogen nk
cell defici optim
enhanc adcc combin anti-
vivo
adopt corpor present wainwright co
adopt nk cell therapi four function
high
delet
optim nk cell biolog
signal domain target
complex could promot
surviv persist
reduc depend
adopt corpor present wainwright co
lesson bcma-target cell
expans persist may correl respons
karmma studi peak cell expans
peripher blood significantli correl respons correl
respons cell persist report
clinic
trial
discuss subsequ correl on-going
respons persist cell determin
patient half cell present half without
ohowev unlik studi peak car cell expans
correl respons howev data
potenti immatur patient relaps discern
importantli depth respons deeper
autolog hsct set
longer durabl
provid explan
experi test
first block best
induc orr patient cr mpf month
excel context standard-of-car salvag set mpf rang month
newer program potenti superior least crr perspect believ could translat higher
cell peak around two month post-infus collaps lower-limit quantit
month
emerg data field elabor upon subsequ point correl durabl respons peak
expans ts suggest durabl may immateri
addit experi hsct suggest abil drive deeper respons patient mrd neg
vs vgpr like driver long-term surviv benefit potenti valid refer
aim deep responsesth bottom-line
depth respons correl durabl
mm patient treat autolog stem cell transplant os correl depth initi
group vgpr pr togeth compar sd/pd show clear differenti outcom
patient cr exhibit greater mpf mo compar respons criteria
cell qualiti
like superior allogen ts
examin patient multipl myeloma reveal
differ health cell impli even earli mm
patient poorer qualiti cell
overal cell count mm patient half
number nave cell much higher healthi donor
mm patient also lower level effector cell
indic overal less differenti cell popul
continu next page
cell qualiti correl clinic outcom mm
multipl myeloma patient either one median prior line post-induct group
relapsed/refractori median prior line examin respons autolog
post-induct patient gener better product relapsed/refractori subject top
memori cell vs middl greater ratio vs
bottom greater ex vivo cell expans doubl vs
less heavili treat patient gener better cell product compar
relapse/refractori group whole also focus relapsed/refractori patient
pr better product still superior post-infus group thu
even better respond relapsed/refractori group product averag
inferior earlier line patient product
studi show detriment effect multipl chemotherapeut line treatment
cell compart importantli hobbl cell product subsequ
think data support util healthi donor allogen cell
potenti perform much better product gener relapsed/refractori patient
select target locu
rational select calibr itam
insert trac locu way forward
select target code sequenc tcr locu
construct
trac locu
exhaust marker
guid rna grna target end first exon
electropor mrna grna yield high
knockout frequenc note knock-in proport
aav dose exceed moi
cdna
adopt natur wainwright co
stress test
t-cell dosag
limit differ t-cell
trac-car cell
construct
potent everi t-cell
cell phenotyp evalu five day post-incub cultur
presenc antigen show trac-car cell
maintain phenotyp analog un-transduc cell
 mainli compos nave central memori
cell phenotyp associ greater vivo anti-tumor
activ exhaust differenti
trac exhibit superior activ tradit
gener cell line superior cell
adopt natur wainwright co
select calibr itam activ exquisit control cell destini
exist substanti redund
signal incorpor three itam
select mutat itam construct
gener higher central memori cell
phenotyp superior vivo prolifer durabl
tradit
singl itam-contain mutant term
gener addit anoth mutant term retain two distal
itam evalu ex vivo vivo
adopt natur medicin wainwright co
insert trac locu could way forward
efficaci tumor erad gradual decreas
increasingli distal posit function itam
design achiev durabl
complet remiss lowest cell dose treatment
slightli delay tumor progress compar
wild-typ relaps eventu develop
construct exhibit increas
popul tcm cell time
associ enhanc persist
capabl elicit effect recal
adopt natur medicin wainwright co
novel consist co-stim
domain modifi signal domain optim
effector cell persist anti-tumor potenc
trac target integr trac
region regul endogen control tcr
express optim perform
tcr null bi-allel disrupt trac clonal level
complet remov tcr express
elimin
possibl gvhd allogen
display enhanc control tumor growth
dissemin xenograft model lymphoblast leukemia
adopt natur medicin wainwright co
ix off-the-shelf nk cell deriv clonal
engin master ipsc line engin
modifi receptor enabl high-affin bind cleavag protect
clinic rational modifi studi show larg benefit allel breast
retrospect studi indic greater clinic benefit patient harbor allel
nk cell aml almost yet
nkaml shine beacon aspir benchmark
pediatr high risk elderli aml haplo-nk cell intervent effect implement prior relaps
modifi receptor enabl high-affin bind cleavag protect
allogen nk cell nativ replac
modifi amelior cleavag
build upon backbon ipsc-nk serv
backbon
nk-cell express receptor bind fc region
antibodi bound antigen cell surfac bind
fc region induc adcc kill antigen-bear cell
stimul secret cytokin
two variant allel
vv homozygos occur popul
allel bind higher affin fc region engend
greater nk-cell activ associ improv
outcom mani indic
demonstr
cleavage-resist nk cell
deriv peripher blood unmodifi ipsc-nk cell
evalu number cell
stimul bottom panel
three sourc nk cell normal
stimul follow stimul
pma/ionomycin nk cell type lost express except
due cleavage-resist modif
note stimul raji
 cell alon
suffici loss express combin anti-
rituximab suffici induc nk cell stimul
loss except nk cell
dose-escal two
regimen initi octob
decemb two patient treat
one regimen receiv three dose
grade neurotox graft
vs host diseas gvhd observ thu far
first patient administ treatment
aml exhibit evid product chimer bone
marrow morpholog detect leukemia
exhibit evid hematopoiet recoveri
follow initi lymphodeplet regimen
note administ unit
dose subcutan dose
therapeut wainwright co
decemb second ind
approv treatment solid tumor combin
mab egfr mab
discuss subsequ believ explor
combin well found initi
patient solid tumor previous fail anti-
expect
focus avelumab
studi show larg benefit allel breast cancer
clinic rational modifi
vitro data indic trastuzumab bind allel
nsabp phase studi women
breast cancer treat chemotherapi plu trastuzumab
retrospect analysi disease-fre surviv
statist signific surviv benefit patient
sophia phase studi evalu margetuximab
chemotherapi patient previous treat two prior
treatment metastat set
median os patient bear vv allel favor
trastuzumab although vv allel patient repres
enrol popul outcom valid trastuzumab
two studi strongli suggest surviv benefit
patient allel
impli nk cell tune
could impact patient ff genotyp
similar overal outcom sophia program
stat-sig benefit
ff fv allele-bear
patient receiv margetuximab trend toward os
event
ff fv
greater benefit rituximab fll patient harbor allel
group patient follicular lymphoma fll treat
rituximab retrospect assess len
evalu demograph characterist patient indic
trend older patient vv genotyp wherea younger
patient ff allel see tabl
howev test compar two shi signific
could suggest patient vv genotyp
abl stave fll longer patient natur endow
ff genotyp
note frequenc vv genotyp gener popul
estim henc frequenc studi
line clin invest sep
retrospect analysi patient vv allel reveal
significantli longer median vs day patient
 allel see bottom
suggest combin rituximab would
benefici fll perhap b-cell lymphoma
reflect preclin data
journal clinic oncolog doi
allel like benefici egfr head neck cancer
patient stage ii/iv head neck cancer evalu impact
cetuximab
overal surviv patient segreg genotyp
reveal trend toward clinic benefit vv allel howev
due small number patient vv group statist
signific correl obtain
nonetheless believ anoth clinic exampl albeit
handicap small number point potenti benefit
use combin
kra wild-typ mcrc may outlier
benefit patient harbor f-allel
germlin dna isol kra wt-mcrc patient
phase studi evalu treatment
patient allel experienc shorter
month patient ff genotyp month
result sharp contrast studi rituximab
trastuzumab demonstr clinic advantag patient
 allel
plausibl explan result propos
furthermor studi mcrc patient treat
cetuximab wild-typ kra locu found
statist signific advantag vv patient compar
f-carrier vs month
outcom accord rituximab trastuzumab
signific differ orr genotyp observ
popul subset kra mutat patient
orr tend higher vv patient f-carrier vs
 ns
data suggest kra wild-typ mcrc patient may
european journal cancer volum issu juli page
doi journal clinic oncolog
nk cell aml almost yet
posit prognost
cohort
reconstitut post-transplant
overcom mhc barrier kir
ligand mismatch mediat potent
clinic experi haploident
nk cell infus sibl parent
children follow subcutan
stimul nk prolifer activ
poor prognosi aml patient
select deplet
lymphoid organ pb could enhanc
select deplet achiev
compos amino acid sequenc
diphtheria toxin follow truncat amino
acid sequenc
time effect kill
cell bear receptor chain
express lower affin receptor
compar
clinic outcom elabor
mainten standard ld-
treg deplet enhanc haplo-nk cell activ aml
among patient cohort
deplet achiev
remiss cr incomplet
cells/ml platelet recoveri
day median durat
remiss month rang
month ci
cohort compar
deplet cohort result
remiss day
 median durat
remiss cohort month
treg deplet lead nk-cell persist expans
cohort patient
detect donor nk cell vivo
contrast host treg deplet
associ higher rate
success donor nk-cell expans
nk-cell expans
magnitud
also higher treg deplet
nk-cell count day cells/ml
rang cells/ml nk
respect failur expand nk
cell correl diseas burden
count percentag blast
immunolog paramet baselin
pb treg frequenc measur cohort
number inject receiv
influenc nk-cell expans addit
correl
incid nk-cell expans
method nk-cell product manufactur
nkaml shine beacon aspir benchmark
nkaml studi assess feasibl haploident nk cell infus
immunosuppress regimen children year age diagnos
aml complet chemotherapi first complet remiss
underli premis evalu nk cell base transplant lieu
tradit hsct carri risk procedur mortal
statu post chimer nk cell dose
mg/kg day fludarabin
day follow kir-hla
cell six dose million
patient mrd-neg time
enrol studi patient toler
dose cyclophosphamid fludarabin
show accept nonhematolog
journal clinic oncolog doi
nkaml shine beacon aspir benchmark
nkaml studi median follow-up time day rang
day patient remain remiss event-fre surviv
estim ci haplo nk cell provid
altern allogen hsct associ relaps rate
treatment-rel mortal rate approxim
patient transient nk cell engraft
median day rang day
median peak nk cell chimer donor rang
three patient continu
detect donor nk cell week rang
expans kir-mismatch nk cell
observ nine patient kir-mismatch
donor median peak expans day
rang day
journal clinic oncolog doi
pediatr high risk elderli aml
haplo-nk cell intervent effect implement prior relaps
one patient activ diseas achiev transient cr wherea
patient clinic benefit patient molecular relaps achiev cr
last month respect three patient cr
diseas free month
high risk aml patient median
age receiv nk cell infus
baselin five patient activ diseas
two molecular
relaps six
chemotherapi flu mg/mq day
cy g/mq day day cy
administr patient receiv nk-cell
infus day follow
subcutan administr
iu/d three time weekli week
pediatr high risk elderli aml
haplo-nk cell intervent effect implement prior relaps
increas concentr donor chimer lymphodeplet
recipi nk-cell infus cell enumer
pb patient flow cytometri differ time point nk-cell
infus c-d percentag donor chimer test whole
blood evalu pb bm
sinc children weigh less adult median number infus nk
cell significantli higher nkaml studi present trial
differ may partial explain discrep clinic result
suggest adult patient clinic effect nk-cell therapi may
implement increas number infus nk cell
kinet donor-versus-recipi alloreact nk-cell clone nk-cell
infus nk clone kill recipi target detect donor
recipi day day nk-cell infus
respond directli mab dose
depend stimul observ anti-
compar nk cell deriv patient
combin rituximab effect kill
lymphoma cell unmodifi ipsc-nk cell
nk cell deriv pbnk incub
lymphoma cell raji cell apoptosi raji cell
measur
pbnk cell alon effect
kill raji cell make sens cell
express hla recal nk cell inhibit mhc
fc domain
pbnk cell combin
exhibit enhanc cell kill due nk cell
recognit
igg-typ mab
rituximab rel pbnk cell alon
modestli lethal rel pbnk cell
would expect benefit becom
pronounc time patient without
allel specifi
surprisingli unmodifi ipsc-nk cell slightli
increas cell kill presenc
perhap indic incomplet matur nk cell
deriv ipsc
cell exhibit igg-activ intrins cytotox
alon combin anti-
mab evalu cell kill
line
vari express level
cell high express
raji daudi
combin rituximab anti-
potent either agent
lower express
see effect
enhanc addit
suggest cell kill occur due
intrins mechan mhc
tumor
nsg mice inject raji cell lymphomat cell four day later treat pbnk
without mab addit mice treat nk cell inject
tumor burden day assess mice alon modest effect combin
produc robust antitumor effect combin see left
anti-tumor effect plu deepen day slow regress occur see middl
eventu led mice die see right howev mice durabl respons allow surviv beyond
day singl dose
multipl dose enhanc activ
nsg mice treat previou slide rather
treat mice treat weekli four dose
anti-tumor trend gener improv case pbnk
addit greatest decreas seen day
subsequ regress assess median day surviv show
multi-dos greatli enhanc pbnk combin
interestingli despit multipl inject tumor began grow
treat mice day furthermor dose continu three week
thu may explain increas tumor size one possibl explan
dose first week henc may signific contributor
tumor
poster wainwright research
tumor
exhibit activ model ovarian cancer
poster intern journal gynecolog cancer doi
nsg mice inject cell ovarian cancer cell line cell stain green line exhibit
high express rel ovarian cancer cell line shown unstain cell purpl see graph right
four day xeno-engraft mice treat alon combin plu tumor
luminos measur mice treat combin plu plu exhibit greatest reduct
tumor volum slowest
contribut entwin individu
contribut determin experi
model suggest nk cell might offer potenti strategi overcom resist caus
loss
preliminari clinic data safeti immunogen present concern
earli activ singl dose
thought step
nk cell
nk cell possess innat abil detect transform
cell thu key cancer immunosurveil
nk cell attract altern cell immunotherapi
preferenti target
alter cell bodi
without need prior sensit knowledg specif
natur killer nk cell lymphocyt
directli kill abnorm infect cell addit secret
cytokin enhanc innat adapt mechan
immun exampl direct kill initi
releas cytotox granul ultim gener cell debri
captur antigen-pres cell includ macrophag
cell recognit nk cell regul complex
array activ inhibitori interact
dnax-accessori natur
cytotox receptor appear play central role nk cell
recognit myeloma
interact killer immunoglobulin-lik receptor kir
self-major histocompat complex class antigen induc
strong inhibitori signal predomin
human nk cell express antigen isoform
neural cell adhes molecul
approxim nk cell high-dens express
surfac constitut express
high-affin heterotrimer receptor
intermediate-affin heterodimer
trend immunolog
mani trial adopt nk cell-bas immunotherapi
conduct past decad
trial use nk cell isol peripher
blood umbil cord blood nk cell line
trial use adopt transfer allogen nk cell
demonstr safeti gvhd neurotox
typic clinic studi use combin lympho-deplet
chemotherapi cytokin treatment enabl vivo surviv
expans allogen nk cell three week
treatment
cell aneuploid must irradi
administ patient limit
surviv
prolifer nk cellstwo key criteria associ
although nk cell isol peripher blood pb-nk
cell umbil cord blood ucb-nk cell
efficaci aml success solid tumor
produc standard cell popul
provid homogen nk cell popul grown
clinic scale
engin nk cell improv kill
solid tumor evalu clinic
treatment hematolog malign
howev trial util either pb-nk cell cell
well design cell optim nk
principl
optim nk-car form basi off-
engin nk cell activ domain
improv anti-tumor efficaci nk cell especi
solid tumor resist nk cell-medi kill
sinc primari nk cell rel less effici genet
modifi compar cell cell sourc switch
ipsc effici produc nk cell
genet modifi use viral non-vir method
nk cell highli effici protect tumor metastasi
howev shown dysfunct pre-metastat nich environ establish tumor distant organ futur
among strategi employ downregul ligand ligand includ mica/b recogn nk cell
secret factor like shla-g smica/b either inhibit nk cell cytotox interfer nk cell-medi kill tumor cell
nk cell mediat activ without requir hla match therefor nk cell function allogen effector need
collect patient specif hla-match donor
tumor metastat cell frequent develop strategi escap nk cell recognit cytotox
exampl breast cancer cell activ regul pathway promot metastasi escap immunosurveil
nk cell
tumor cell evad cell-medi immun recognit downregul mhc class nk cell well-equip detect
target cell alter reduc express mhc-i via mous kir human receptor
loss receptor affect cytotox nk cell result defect missing-self recognit lead uncontrol tumor growth
henc nk cell undergo educ process interact self-specif inhibitori receptor mhc-i molecul must take
educ nk cell abil elimin tumor cell control cancer growth metastasi
base experi
nk cell random unrel healthi
donor may result cell
complet mismatch mhc
class allel express donor
recipi infus strategi
allow donorrecipi kir ligand
mismatch overcom limit
due small potenti donor pool
patient malign
lymphoma
advanc recurr solid tumor
fail benefit standard treatment
enrol studi
evalu patient treat
three weekli infus cells/kg
lymphoma patient stabl
diseas sd along seven solid
cancer patient sd best
respons supplement
lymphodeplet use
receiv higher
express nk cell enhanc
kir haplotyp associ
higher incid sd
base outcom gastroesophag
nk cell deriv patient
individu base standard pbmc
harvest peripher blood follow
expans
gastroesophag enrol
cohort cohort cohort
cell per dose nk cell
intraven inject min day
patient show tumor shrinkag
observ period week
last treatment patient
sd supplement
lymphodeplet use
chemokin receptor
rel highli express
expand nk cell median
popul
respons evalu patient
vitro cytotox pbmc
target increas patient post
cell-depend kill cancer cell requir
effici present tumor antigen human leukocyt
hla class hla-i genotyp link differenti
inflammatori condit
immun respons infect
hla-i molecul highli polymorph variat locat
peptide-bind region
variant bind select repertoir peptid ligand
individu homozyg least one hla-i locu would pre-
dict present smaller less divers repertoir tumor- deriv
neoantigen cytotox lymphocyt compar
person heterozyg class locu
maxim heterozygos hla-i loci improv
overal surviv
compar patient homozyg least one
two independ melanoma cohort patient
supertyp extend surviv
supertyp includ somat loh
hla-i associ poor outcom
clinic outcom includ subsequ slide
drawn retrospect analysi two cohort patient
treat icb
cohort includ patient treat anti-pd-
within cohort patient advanc melanoma
patient advanc non-smal cell lung cancer nsclc
nsclc patient treat monotherapi
includ melanoma nsclc
patient treat drug target
combin
hla-i homozygos least one locu associ
reduc surviv cohort
number somat mutat tumor statist
differ homozyg heterozyg patient
associ hla-i homozygos reduc surviv
remain signific multivari cox regress model
analyz mutat load tumor stage age drug class
adapt scienc wainwright co
clinic rational hla-i gene influenc patient respons icb
analysi present previou page
expand includ patient cohort
determin whether effect homozygos may due
singl hla-i locu combin differ loci
homozygos one hla-i locu
associ signific reduct overal surviv
interestingli effect homozygos surviv due
specif hla-i locu seem mostli associ hla-b
hla-c
associ hla-b explain fact
hla-b gener express higher level cell
surfac other
hla-b allel bind greater divers peptid
addit amino acid bind pocket hla-
allel broadli hydrophob contrast pocket
hla-b allel accommod greater varieti
patient loh hla-i associ reduc
furthermor effect loh hla-i surviv
greater patient whose tumor contain low mutat
hla-i gene influenc patient respons icb
patient-specif hla-i genotyp well somat
alter tumor impact clinic outcom icb
suggest factor could consid design
hla-i homozygos loh repres genet barrier
effect immunotherapi altern way har
immun system may necessari maxim clinic benefit
clinic rational loh enrich non-respond
loss like common mechan
resist therapi target
tumor biopsi metastat
melanoma patient treat icb point mutat
delet loh
note patient progress diseas
essenti compon mhc class antigen
two independ cohort melanoma
patient treat ipilimumab pembrolizumab
loh enrich threefold non-respond vs
loh associ wors os
loss copi found non-
evid associ loh overlap
poorer os exclus cohort
importantli mutat observ pre-
treatment sampl henc patient potenti
enrich benefit
model suggest nk cell might offer potenti strategi overcom resist
caus loss
import clinic question whether
defici melanoma target nk cell
given known inhibitori effect hla class
protein nk cell
mous model develop test whether
use technolog guid rna
delet introduc melanoma cell
line deriv pten/ transgen
mimic evolv human tumor mixtur
parent cell
tag uniqu marker transplant
mice presenc absenc nk cell
antibodi use deplet nk cell
mice lack nk cell show signific
increas rel tumor
issu safeti immunogen
studi open-label multi-dos phase
clinic trial treatment advanc solid tumor
novemb data cutoff patient
combin ici treat
monotherapi arm four
dlt sae grade
incid neurotox gvhd
report
patient initi second treatment cycl
eight nine patient complet second
current pend
initi second treatment cycl
t-cell compart nine patient evalu
tcr repertoir analysi conduct multipl time
point follow treatment demonstr
maximum t-cell clone patient
reconstitut t-cell compart compris pre-
exist low-frequ t-cell clone suggest
robust t-cell respons evid
antibodi repertoir patient analyz
target six hla class type express
among patient singl anti-hla antibodi
mean fluoresc intens mfi level
detect singl patient suggest robust
b-cell respons evid
therapeut decemb pr file
await augment multidos expans appropri stratifi patient
activitytoo earli
monotherapi arm two
three patient
cell per dose cohort two
five patient cell
ici combin arm
two
three patient
respons stabl diseas per
ici
combin arm current
undergo treatment
therapeut decemb pr
thought data challeng step
clinic observ circumv multipl
obstacl clinic observ lead loh
primarili deriv melanoma henc
extrapol indic may
translat
spectrum indic includ colon nsclc etc
may inher suscept icb
henc sd best respons entir surpris
furthermor patient prospect select
base loh loci limit scope
interpret data
final clinic observ base
singl dose might suffici elicit
respons subject either resist refractori
oin dose-expans stage phase
studi would administ cell per
dose combin ici therapi
respons develop
lymphoid-bias
precursor cell eventu commit nk
variant nk cell
approxim nk cell circul
exert cytotox releas
hand popul particip
inflammatori respons nk-sensit target
cytokin secret
note short half-lif like
dose limit like appear vls-relat
henc move toward design bias alpha il-
exampl synthorx acquir sanofi
sny-not rate decemb
prefer would steer away
incorpor either futur clinic
program might circumv
half-lif
vls-relat challeng tradit
nk cell paradox
art need perfect scienc
anti-tumor activ nk cell depend educ licens surviv vivo along abil counteract
potenti suppress host immun compon develop nk cell surveil escap mechan
approxim nk cell high-dens express surfac constitut
express high-affin heterotrimer receptor intermediate-affin heterodimer
nineti percent human nk cell low-dens express express intermediate-affin
vitro picomolar pm concentr bind high-affin express nk cell result strong
prolif respons seen nk cell
vivo surviv prolifer nk cell certainti activ ex vivo
exampl addict cytokin result mark reduct nk cell activ anim model upon cytokin withdraw
furthermor anim model nk cell undergo apoptosi upon contact vascular endothelium
interestingli vivo apoptosi happen nk cell
least two clinic studi demonstr benefit continu treatment nk cell infus
shown select promot nk cell expans persist week vivo
dose critic number tumor infiltr nk cell like de minimi henc subtherapeut
set nk cell therapi host treg interfer nk-cell prolifer expans treg uniqu
depend high affin receptor chain function surviv mediat strongest prolif
signal treg
associ vl would make hard deciph therapeut benefit small studi focus melanoma
rcc view
nk cell clinic experi mm
clinic outcom either fresh
either cryopreserv nk cell
combin evalu
eight multipl myeloma patient
day prior nk cell
therapi downregul hla-i express
upregul trial receptor mm
dex/flu/ci downregul treg
nk cells/kg infus
administr
dose daili sc
vivo expans
observ five patient
highest nk-cell
count note two subject
receiv cell produc high
concentr u/ml
among evalu patient one pr anoth tempo
diseas progress decreas neither patient requir therapi
infus fresh nk cell correl vivo expans subsequ
nk treg ratio higher day day day
treg level peak highlight challeng simultan therapi
select expans nk
cell continu vivo
infus result
bone marrow progenitor
nk-cell
death rather prolifer
matur nk cell peripheri
concentr compar
found vivo
therapi prolifer day
exit cell cycl
howev nk cell travers
vivo phase cell
cycl
concentr
program cell death nk cell
effect rest
cell expand vivo
cell expand vivo
transit cell cycl dot plot
analyz flow
region indic fraction subset
compris percentag
intens given
along ordin fitc fluoresc intens
nk cell
 cell repres
shown right column
nk cell
peripher blood stem cell transplant risk procedur mortal
protmun initi clinic profil critic comparison
magenta cord blood potenti rival peripher blood
stem-cel sourc correl risk acut graft versu host diseas agvhd
peripher blood stem-cel sourc correl agvhd use stem-cel sourc
despit higher risk agvhd peripher blood stem cell transplant pb-sct bear lowest mortal
phase studi protmun pb-sct well-toler event graft failur
patient protmun engraft rapidli agvhd rate similar peer superior os
aml protmun engraft rapidli caus chronic-gvhd rate higher peer
estim phase data protmun hematolog malign could read-out
hematopoiet stem cell transplant cur option
variou hematolog malign aml cml nhl
mm prosecut anti-tumor activ donor cell
recognit tumor antigen malign host cell
agvhd unmatch donor
main risk use allogen graft versu host diseas
gvhd acut gvhd usual occur within day
acut gvhd occur allo sct recipi despit
intens prophylact immunosuppress develop
moder grade sever
 grade agvhd
associ signific decreas surviv
elucid risk factor agvhd adult hematolog
malign underw sct
regardless precondit regimen
 myeloabl
peripher blood stem cell like induc agvhd bone
exampl compar treatment categori vs vs vs
csa
tacrolimu
uptod prevent acut graft-versus-host diseas updat aug blood doi
nonetheless peripher blood-deriv sct common transplant
number patient receiv hct
transplant
perform us allogen
sourc broken sourc stem
cell bone marrow cord blood peripher blood see top
among hematolog malign number patient
receiv hct allogen sourc autolog list
top tabl also calcul contribut
allogen sourc total number allogen
sourc contribut allogen hct
contribut sourc differ slightli
indic peripher blood contribut
allogen perform
thu stem-cel sourc like caus agvhd
often select base lower
mortal elabor upon subsequ
center intern blood marrow transplant cell sourc diseas categori donor type last updat decemb
peripher blood-deriv stem cell reduc risk mortal
reason peripher blood stem cell
prefer choic stem cell sourc due trend
toward lower incid transplant-rel mortal see
tabl compar vs vs
thu risk agvhd higher peripher
mortal lower
risk
transplant femal donor male recipi
transplant hla-mismatch donor prior cmv
infect recipi donor presenc abo mismatch
advanc diseas statu
transplant
associ significantli increas risk transplant-
multivari analys risk factor transplant-rel mortal
effort lower risk agvhd peripheral-blood deriv stem cell protmun product formul
enhanc biolog properti therapeut function graft cell
protmun allogen stem-cel product gener ex vivo stimul donor peripher blood two small molecul
dimethyl prostaglandin dexamethason subsequ use treat patient
phase clinic trial evalu protmun seven adult subject hematolog malign undergo match unrel
peripher blood hct follow myeloabl condit undergo prophylact methotrex tacrolimu gvhd first
set data report novemb see tabl
protmun well-toler event graft failur sae
protmun rapidli engraft gvhd concern remain
agvhd
protmun reveal rapid rate
engraft high rate agvhd
mirror standard peripher blood-
though good os last day
protmun aml result rapid
engraft rate agvhd
par
case result higher rate chronic
gvhd signific concern earli
rate surviv appear trend toward
norm
overal protmun appear
superior standard pb-deriv sct
pt treat
pt engraft
pt gr
pt mod-sev
 wainwright co research adapt file march hematol oncol doi
protmun dose-expans potenti data readout
protmun current midst phase expans portion protect studi adult patient
novemb protect fulli enrol think may impli initi read acut gvhd sometim
magenta cord blood potenti rival peripher blood
cord blood cell interest altern peripher blood-deriv
stem cell
wide varieti avail hla haplotyp
make possibl strong donor/recipi match much higher
therebi greatli lessen chanc gvhd complic howev
cord blood often come volum small use allogen
transplant adult
magenta rate allogen cell product
gener umbil cord blood expand use
investigator-sponsor phase trial begin mgta-
given patient hematolog malign follow
myeloabl condit reduced-intens condit
induc cell expans fold rang see top graph
trial cryopreserv initi
decemb patient high-risk malign eighteen patient
condit engraft rapid see graph howev myeloabl
condit caus grade acut gvhd see tabl higher
cumul incid patient treat
myeloabl non-myeloabl peripher blood bone marrow-
deriv stem cell approxim
see idea innov promis current limit
requir process time receipt cord-blood product
releas henc rapidli progress patient often case
aml may amen compound problem librari
may abl built cryopreserv sampl
viabl day
pt treat
pt engraft day
pt gr agvhd
pt mod-sev cgvhd day
magenta file march blood supplement doi
licens deal platform
anticip oper loss respect
exit approxim cash equival exclud up-front payment
janssen april togeth suffici fund oper
although financi well-posit near-term model assum addit capit rais
share fund pipelin initi note stock current trade
quick look burn period cash total cash cash period cash yr qs qs qs qs yr qs qs qs qs yr inc
septemb enter collabor option agreement joint
develop commerci two off-the-shelf ipsc-deriv t-cell product candid t-cell target
antigen product disclos
term agreement
would contribut bind domain target lymphoblast leukemia
subject preclin option exercis ono would right asia
aggreg total mileston payment made ono
elig receiv tier rang mid-singl low double-digit percentag royalti net sale
would contribut bind domain target solid tumor
ono would gain world-wide right opt-in right develop commerci europ
profit-shar arrang
aggreg total mileston payment made ono
elig receiv tier rang mid-singl low double-digit percentag royalti net sale
preclin fund
up-front payment
commit research fund
addit conting fee
look proprietari tumor-target antigen binder
april janssen biotech enter collabor agreement develop ipsc-deriv nk t-
cell product candid treatment hematolog malign solid tumor janssen would contribut
proprietari antigen bind domain direct four tumor-associ antigen target
term agreement
would research construct ipsc-deriv nk t-cell product candid direct janssen cancer
target perform preclin develop collabor candid
aggreg up-front equiti invest total made janssen
up-front payment
stock purchas agreement common share per share april total
janssen would fulli fund research preclin develop ind-en activ perform
aggreg total mileston payment made janssen roughli
develop regulatori mileston
commerci mileston payment
elig receiv tier royalti payment double-digit percentag rang mid-teen net sale global
therapeut file april
program pipelin
regen medicin vivo
approach gsd ia dmd cf
rate
gene therapi hemophilia fabri
tauopathi als/ftld hd
phase lead program
partnership servier privat
partnership kite gilead
rate compani
phase lead program
partnership allogen
phase allianc allogen
aml
rate
ind-clear allianc
phase lead program
nhl
partnership servier
corpor present wainwright co estim market cap may
thousand except per share data
good sold
research develop
gener administr
total incom expens
loss incom tax
unreal gain loss available-for-sal secur net
thousand except per share data
flow oper activ
amort debt discount debt issuanc cost
accret amort premium discount invest net
amort collabor contract asset
issuanc common stock licens agreement
extinguish debt net
prepaid expens asset
account payabl accru expens
right-of-us asset leas liabil net
net cash provid use oper activ
flow invest activ
purchas properti equip
purchas invest
matur invest
net cash provid use invest activ
flow financ activ
issuanc common stock equiti incent plan net repurchas iss
proce public offer comm stock net issu cost
proce cirm award
princip repay long-term debt
net cash provid use financ activ
net increas decreas cash/cash equival
 equival begin period
 equival end period
thousand except per share data
cash equival
short-term invest relat matur receiv
prepaid expens current asset
properti equip net
liabil stockhold equiti
defer revenu net current portion
cirm award liabil net current portion
oper leas liabil net current portion
long-term debt net current portion
accumul comprehens gain loss
total liabil stockhold equiti
outlook ratio analysi enterpris valu
burn period cash oper
total cash cash equival
period cash remain
ebitda sale
return asset roa
return equiti roe
materi confidenti intend use institut account defin finra rule may also
privileg otherwis protect work product immun legal rule receiv mistak pleas let
us know email repli delet system may copi messag
disclos content anyon integr secur messag guarante internet
 wainwright co llc rate wainwright employ three tier rate system evalu
potenti return risk associ own common equiti share rate firm expect return given
equiti measur rel basi compani sector price object calcul estim
potenti movement price given equiti could reach provid certain target met defin time horizon
price object subject extern factor includ industri event market volatil
market outperform buy common stock compani expect outperform passiv index compris
common stock compani within sector
market perform neutral common stock compani expect mimic perform passiv index
compris common stock compani within sector
market under-perform sell common stock compani expect under-perform passiv index compris
common stock compani within sector
rate price target histori inc fate-u
rate price target histori inc allo-u
rate price target histori precis bioscienc inc dtil-u
rate price target histori genmab a/ gmab-u
rate price target histori inc immu-u
rate price target histori inc sgmo-u
relat compani mention report
invest bank servic includ limit act manager/co-manag underwrit placement
secur act financi advisor and/or provid corpor financ capit markets-rel servic compani
one affili subsidiari within past month
distribut rate tabl may
 wainwright co llc firm member finra sipc regist broker-deal
debjit chattopadhyay earl desouza certifi view express report accur reflect person
view subject secur issuer discuss part compens directli
indirectli relat specif recommend view express research report neither
member household offic director advisori board member compani
none research analyst research analyst household financi interest secur
inc inc precis bioscienc inc genmab a/ inc
inc includ without limit option right warrant futur long short posit
april neither firm affili benefici class common equiti secur
inc inc precis bioscienc inc genmab a/ inc
neither research analyst firm know reason know materi conflict interest time
public research report
research analyst princip respons prepar report receiv compens base upon
specif invest bank servic transact compens base factor includ total revenu profit
firm substanti portion deriv invest bank servic
firm affili receiv compens inc inc precis
bioscienc inc inc inc invest bank servic within twelv month
seek compens compani mention report invest bank servic within three
month follow public research report
firm affili receiv compens genmab a/ invest bank servic within twelv month
seek compens compani mention report invest bank servic within three
month follow public research report
 wainwright co llc manag co-manag public offer secur genmab a/ past month
firm make market inc inc precis bioscienc inc genmab
a/ inc inc date research report
secur compani discuss report may unsuit investor depend specif invest
object financi posit past perform guarante futur result report offer inform
purpos constitut offer solicit buy sell secur discuss herein jurisdict
would prohibit research report intend provid tax advic use provid tax advic
person electron version wainwright co llc research report made avail client simultan
part report may reproduc form without express permiss wainwright co llc addit
 wainwright co llc provid individu tailor invest advic research report research report
intend provid person invest advic take account specif invest object financi
situat particular need specif person investor seek financi advic regard appropri
invest financi instrument implement invest strategi discuss recommend research report
 wainwright co llc affili salespeopl trader profession may provid oral written market
commentari trade strategi reflect opinion contrari opinion express research report
 wainwright co llc affili offic director employe exclud analyst time time
long short posit act princip buy sell secur deriv includ option warrant
thereof cover compani refer research report
inform contain herein base sourc believ reliabl guarante us
accur purport complet statement summari avail data compani industri secur
discuss report opinion estim includ report constitut analyst judgment date
report subject chang without notic
secur financi instrument discuss research report may lose valu insur feder
deposit insur corpor subject invest risk includ possibl loss princip amount invest
